Comparative evaluation of cefadroxil and cephalexin in children and adolescents with pyodermas

C. W. Linder, K. Nelson, S. Paryani, J. R. Stallworth, J. L. Blumer, J. Wendt, W. Derrick, J. M. McCarty, J. L. Murillo, F. W. Tecklenburg, T. Yamauchi, C. Hains

Research output: Contribution to journalArticle

6 Citations (Scopus)

Abstract

This randomized, multicenter study compared the safety and efficacy of cefadroxil with that of cephalexin for the treatment of pyodermas in children and adolescents (1-18 years of age). Cefadroxil was given as a single oral daily dose of 30 mg/kg, and cephalexin 30 mg/kg/day was given in two divided doses. The maximum daily dose for both drugs was 1 gm, and treatment was administered for 10 days. Clinical and bacteriologic evaluations were made on days 4 or 5 during therapy and 2 to 4 days after therapy was completed. Of the 462 patients enrolled in the study, 156 patients in the cefadroxil group and 133 patients in the cephalexin group were evaluable. Staphylococcus aureus (56% of isolates) and Streptococcus pyogenes (39% of isolates) were isolated most frequently. The bacteriologic response was statistically greater in the patients treated with cefadroxil than in those treated with cephalexin (96% versus 89%; P = 0.042). A satisfactory clinical response was reported in 147 (94%) cefadroxil-treated patients and 122 (92%) cephalexin-treated patients (P = 0.476). The overall effective response to treatment was significantly higher with cefadroxil than with cephalexin (94% versus 86%; P = 0.024). Compliance with 9 or 10 days of therapy was similar in both treatment groups, although there was a difference between the two treatment groups with respect to completion of medication regimen: 95% of patients taking cefadroxil once daily-versus 65% of patients taking cephalexin twice daily-took 100% of their medication (P < 0.0001). Adverse events were infrequent and mild. The results of this study demonstrate that once-daily cefadroxil offers greater bacteriologic eradication and a better overall effective response than twice-daily cephalexin for the treatment of pyodermas caused by gram-positive pathogens in children and adolescents.

Original languageEnglish (US)
Pages (from-to)46-56
Number of pages11
JournalClinical Therapeutics
Volume15
Issue number1
StatePublished - Apr 9 1993
Externally publishedYes

Fingerprint

Cefadroxil
Cephalexin
Therapeutics
Streptococcus pyogenes
Multicenter Studies
Staphylococcus aureus

ASJC Scopus subject areas

  • Pharmacology
  • Pharmacology (medical)

Cite this

Linder, C. W., Nelson, K., Paryani, S., Stallworth, J. R., Blumer, J. L., Wendt, J., ... Hains, C. (1993). Comparative evaluation of cefadroxil and cephalexin in children and adolescents with pyodermas. Clinical Therapeutics, 15(1), 46-56.

Comparative evaluation of cefadroxil and cephalexin in children and adolescents with pyodermas. / Linder, C. W.; Nelson, K.; Paryani, S.; Stallworth, J. R.; Blumer, J. L.; Wendt, J.; Derrick, W.; McCarty, J. M.; Murillo, J. L.; Tecklenburg, F. W.; Yamauchi, T.; Hains, C.

In: Clinical Therapeutics, Vol. 15, No. 1, 09.04.1993, p. 46-56.

Research output: Contribution to journalArticle

Linder, CW, Nelson, K, Paryani, S, Stallworth, JR, Blumer, JL, Wendt, J, Derrick, W, McCarty, JM, Murillo, JL, Tecklenburg, FW, Yamauchi, T & Hains, C 1993, 'Comparative evaluation of cefadroxil and cephalexin in children and adolescents with pyodermas', Clinical Therapeutics, vol. 15, no. 1, pp. 46-56.
Linder CW, Nelson K, Paryani S, Stallworth JR, Blumer JL, Wendt J et al. Comparative evaluation of cefadroxil and cephalexin in children and adolescents with pyodermas. Clinical Therapeutics. 1993 Apr 9;15(1):46-56.
Linder, C. W. ; Nelson, K. ; Paryani, S. ; Stallworth, J. R. ; Blumer, J. L. ; Wendt, J. ; Derrick, W. ; McCarty, J. M. ; Murillo, J. L. ; Tecklenburg, F. W. ; Yamauchi, T. ; Hains, C. / Comparative evaluation of cefadroxil and cephalexin in children and adolescents with pyodermas. In: Clinical Therapeutics. 1993 ; Vol. 15, No. 1. pp. 46-56.
@article{614737a43c5f4e7d922128470abba71c,
title = "Comparative evaluation of cefadroxil and cephalexin in children and adolescents with pyodermas",
abstract = "This randomized, multicenter study compared the safety and efficacy of cefadroxil with that of cephalexin for the treatment of pyodermas in children and adolescents (1-18 years of age). Cefadroxil was given as a single oral daily dose of 30 mg/kg, and cephalexin 30 mg/kg/day was given in two divided doses. The maximum daily dose for both drugs was 1 gm, and treatment was administered for 10 days. Clinical and bacteriologic evaluations were made on days 4 or 5 during therapy and 2 to 4 days after therapy was completed. Of the 462 patients enrolled in the study, 156 patients in the cefadroxil group and 133 patients in the cephalexin group were evaluable. Staphylococcus aureus (56{\%} of isolates) and Streptococcus pyogenes (39{\%} of isolates) were isolated most frequently. The bacteriologic response was statistically greater in the patients treated with cefadroxil than in those treated with cephalexin (96{\%} versus 89{\%}; P = 0.042). A satisfactory clinical response was reported in 147 (94{\%}) cefadroxil-treated patients and 122 (92{\%}) cephalexin-treated patients (P = 0.476). The overall effective response to treatment was significantly higher with cefadroxil than with cephalexin (94{\%} versus 86{\%}; P = 0.024). Compliance with 9 or 10 days of therapy was similar in both treatment groups, although there was a difference between the two treatment groups with respect to completion of medication regimen: 95{\%} of patients taking cefadroxil once daily-versus 65{\%} of patients taking cephalexin twice daily-took 100{\%} of their medication (P < 0.0001). Adverse events were infrequent and mild. The results of this study demonstrate that once-daily cefadroxil offers greater bacteriologic eradication and a better overall effective response than twice-daily cephalexin for the treatment of pyodermas caused by gram-positive pathogens in children and adolescents.",
author = "Linder, {C. W.} and K. Nelson and S. Paryani and Stallworth, {J. R.} and Blumer, {J. L.} and J. Wendt and W. Derrick and McCarty, {J. M.} and Murillo, {J. L.} and Tecklenburg, {F. W.} and T. Yamauchi and C. Hains",
year = "1993",
month = "4",
day = "9",
language = "English (US)",
volume = "15",
pages = "46--56",
journal = "Clinical Therapeutics",
issn = "0149-2918",
publisher = "Excerpta Medica",
number = "1",

}

TY - JOUR

T1 - Comparative evaluation of cefadroxil and cephalexin in children and adolescents with pyodermas

AU - Linder, C. W.

AU - Nelson, K.

AU - Paryani, S.

AU - Stallworth, J. R.

AU - Blumer, J. L.

AU - Wendt, J.

AU - Derrick, W.

AU - McCarty, J. M.

AU - Murillo, J. L.

AU - Tecklenburg, F. W.

AU - Yamauchi, T.

AU - Hains, C.

PY - 1993/4/9

Y1 - 1993/4/9

N2 - This randomized, multicenter study compared the safety and efficacy of cefadroxil with that of cephalexin for the treatment of pyodermas in children and adolescents (1-18 years of age). Cefadroxil was given as a single oral daily dose of 30 mg/kg, and cephalexin 30 mg/kg/day was given in two divided doses. The maximum daily dose for both drugs was 1 gm, and treatment was administered for 10 days. Clinical and bacteriologic evaluations were made on days 4 or 5 during therapy and 2 to 4 days after therapy was completed. Of the 462 patients enrolled in the study, 156 patients in the cefadroxil group and 133 patients in the cephalexin group were evaluable. Staphylococcus aureus (56% of isolates) and Streptococcus pyogenes (39% of isolates) were isolated most frequently. The bacteriologic response was statistically greater in the patients treated with cefadroxil than in those treated with cephalexin (96% versus 89%; P = 0.042). A satisfactory clinical response was reported in 147 (94%) cefadroxil-treated patients and 122 (92%) cephalexin-treated patients (P = 0.476). The overall effective response to treatment was significantly higher with cefadroxil than with cephalexin (94% versus 86%; P = 0.024). Compliance with 9 or 10 days of therapy was similar in both treatment groups, although there was a difference between the two treatment groups with respect to completion of medication regimen: 95% of patients taking cefadroxil once daily-versus 65% of patients taking cephalexin twice daily-took 100% of their medication (P < 0.0001). Adverse events were infrequent and mild. The results of this study demonstrate that once-daily cefadroxil offers greater bacteriologic eradication and a better overall effective response than twice-daily cephalexin for the treatment of pyodermas caused by gram-positive pathogens in children and adolescents.

AB - This randomized, multicenter study compared the safety and efficacy of cefadroxil with that of cephalexin for the treatment of pyodermas in children and adolescents (1-18 years of age). Cefadroxil was given as a single oral daily dose of 30 mg/kg, and cephalexin 30 mg/kg/day was given in two divided doses. The maximum daily dose for both drugs was 1 gm, and treatment was administered for 10 days. Clinical and bacteriologic evaluations were made on days 4 or 5 during therapy and 2 to 4 days after therapy was completed. Of the 462 patients enrolled in the study, 156 patients in the cefadroxil group and 133 patients in the cephalexin group were evaluable. Staphylococcus aureus (56% of isolates) and Streptococcus pyogenes (39% of isolates) were isolated most frequently. The bacteriologic response was statistically greater in the patients treated with cefadroxil than in those treated with cephalexin (96% versus 89%; P = 0.042). A satisfactory clinical response was reported in 147 (94%) cefadroxil-treated patients and 122 (92%) cephalexin-treated patients (P = 0.476). The overall effective response to treatment was significantly higher with cefadroxil than with cephalexin (94% versus 86%; P = 0.024). Compliance with 9 or 10 days of therapy was similar in both treatment groups, although there was a difference between the two treatment groups with respect to completion of medication regimen: 95% of patients taking cefadroxil once daily-versus 65% of patients taking cephalexin twice daily-took 100% of their medication (P < 0.0001). Adverse events were infrequent and mild. The results of this study demonstrate that once-daily cefadroxil offers greater bacteriologic eradication and a better overall effective response than twice-daily cephalexin for the treatment of pyodermas caused by gram-positive pathogens in children and adolescents.

UR - http://www.scopus.com/inward/record.url?scp=0027530254&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0027530254&partnerID=8YFLogxK

M3 - Article

VL - 15

SP - 46

EP - 56

JO - Clinical Therapeutics

JF - Clinical Therapeutics

SN - 0149-2918

IS - 1

ER -